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Background
Soluble guanylyl cyclase (sGC) is a receptor for the signal-
ing molecule nitric oxide (NO). Binding of NO to the sGC
heme moiety leads to increased cGMP synthesis and acti-
vation of cGMP-dependent protein kinase (PKG). As sGC
subunits contain putative phosphorylation sites for PKG,
we tested whether sGC activity is regulated by PKG.
Results
In vitro kinase assays revealed that the α1, but not the β1,
subunit of sGC is a PKG substrate and that the phosphor-
ylation site is located within the first 360 residues of the
α1. A constitutively active form of PKG stimulated incor-
poration of 32P into the α1 subunit in vivo. In addition,
PKG could be detected in sGC immunoprecipitates, sug-
gesting that the two proteins interact in cells. Serine to
alanine mutation of putative PKG sites revealed that Ser64
is the main phosphorylation site for PKG. After generating
a phospho-specific antibody for Ser64, we could demon-
strate that phosphorylation of endogenous sGC on Ser 64
increases in cells and tissues exposed to NO. Phosphoryla-
tion of sGC in cells following SNP stimulation was
blocked by the peptide inhibitor of PKG, DT-3. Wild-type
(wt) sGC when co-expressed in COS cells with a constitu-
tively active form of PKG exhibited lower basal and NO-
stimulated cGMP accumulation. In contrast, the S64A α1/
β1 sGC was resistant to the PKG-induced reduction in
activity. Moreover, co-cultures of endothelial cells with
smooth muscle expressing a phosphorylation-resistant
form of sGC, exhibited higher levels of cGMP (both
basally and following stimulation with bradykinin) com-
pared to co-cultures expressing wild-type sGC. Phosphor-
ylation of the α1 subunit did not alter its ability to form
heterodimers with β1. Using purified sGC and mutants,
we observed that the S64D α1 phosphomimetic/β1 dimer
exhibited lower Vmax; moreover, the decrease in Km after
NO stimulation was less pronounced in S64D α1/β1
compared to wt sGC. Expression of a phosphorylation
deficient form of sGC showed reduced desensitization to
acute NO exposure and allowed for greater VASP phos-
phorylation.
Conclusion
We conclude that PKG phosphorylates sGC on Ser64 of
the α1 subunit and phosphorylation inhibits sGC activity,
establishing a negative feedback loop.
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